Guidelines for High Dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: Education

Scientific literature and patient education texts

Back to Education / Guides & Guidelines

Guidelines for High Dose Chemotherapy and Stem Cell Transplantation for Systemic AL Amyloidosis: EHA-ISA Working Group Guidelines

key information

source: Amyloid: The Official Journal of the International Society of Amyloidosis

year: 2021

authors: Vaishali Sanchorawala, Mario Boccadoro, Morie Gertz, Ute Hegenbart, Efstathios Kastritis, Heather Landau, Peter Mollee, Ashutosh Wechalekar, Giovanni Palladini

summary/abstract:

AL amyloidosis is a systemic amyloidosis and is associated with an underlying plasma cell dyscrasia. High dose intravenous melphalan and autologous stem cell transplantation was developed for the treatment of AL amyloidosis in the early 1990s and was prompted by its success in multiple myeloma. This application has evolved significantly over the past three decades. These guidelines provide a comprehensive assessment of eligibility criteria, stem cell collection and mobilisation strategies and regimens, risk-adapted melphalan dosing, role for induction and consolidation therapies, specific supportive care management, long-term outcome with respect to survival, haematologic response and relapse and organ responses following stem cell transplantation. These guidelines are developed by the experts in the field on behalf of the stem cell transplant working group of the International Society of Amyloidosis (ISA) and European Haematology Association (EHA).

organization: Boston University School of Medicine and Boston Medical Center, USA; University of Torino, Azienda Ospedaliero-Universitaria Citta della Salute e della Scienza di Torino, Italy; Mayo Clinic, Rochester, USA; Heidelberg University Hospital, Germany; National and Kapodistrian University of Athens, Alexandra General Hospital, Greece; Memorial Sloan Kettering Cancer Center, USA; Princess Alexandra Hospital and University of Queensland, Australia; University College London, UK; Amyloidosis Research and Treatment Center, University of Pavia, Italy

DOI: 10.1080/13506129.2021.2002841

read more

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close